2. Academic Validation
  3. Nano-delivery of miRNA inhibiting CENPF combined with cisplatin for bladder cancer treatment

Nano-delivery of miRNA inhibiting CENPF combined with cisplatin for bladder cancer treatment

  • RSC Adv. 2025 Jun 13;15(25):20183-20191. doi: 10.1039/d5ra01513h.
Ruixiang Song 1 2,  Xin Chen 3,  Zhensheng Zhang 2,  Huiqing Wang 2,  Guanghua Chen 2,  Jinshan Xu 2,  Shuxiong Zeng 2,  Wentao Zhang 1 4,  Xudong Yao 1 4
Affiliations

Affiliations

  • 1 Department of Urology, Shanghai Tenth People's Hospital, Tongji University Shanghai 200072 China.
  • 2 Department of Urology, Changhai Hospital, Naval Medical University Shanghai 200433 China.
  • 3 Department of Urology, Zhejiang Qiushi Cardiovascular Hospital Hangzhou 310011 China.
  • 4 Urologic Cancer Institute, School of Medicine, Tongji University Shanghai 200072 China.
PMID: 40519684 DOI: 10.1039/d5ra01513h
Abstract

Bladder Cancer (BCa) presents a substantial global health burden, with high rates of recurrence and metastasis that limit the effectiveness of current therapies. New therapeutic strategies are urgently needed. This study introduces a novel nanotherapeutic approach utilizing polydopamine (PDA) nanoparticles to co-deliver cisplatin and miR-205-5p for BCa treatment. Combination therapy reduces the dose-dependent toxicity of cisplatin while enhancing tumor cell cytotoxicity. miR-205-5p targets centromere protein F (CENPF), a key regulator of Cancer progression. Overexpression of CENPF in BCa correlates with poor prognosis, and miR-205-5p-mediated suppression of CENPF expression inhibits tumor growth. The PDA-based system combines the DNA-damaging effects of cisplatin with the gene-silencing properties of miR-205-5p, resulting in synergistic antitumor activity. This multimodal strategy enhances therapeutic precision and efficacy, providing a promising solution for BCa treatment with significant clinical potential.

Figures
Products